An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report.
증례보고
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: unresectable in-field recurrent cervical cancer
I · Intervention 중재 / 시술
combination therapy with paclitaxel, carboplatin, and pembrolizumab
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.
OpenAlex 토픽 ·
Endometrial and Cervical Cancer Treatments
Cancer Immunotherapy and Biomarkers
Colorectal and Anal Carcinomas
Recurrent cervical cancer after definitive concurrent chemoradiotherapy (CCRT), particularly in-field recurrence, is associated with poor prognosis and limited curative options.
APA
Terumi Shirane, Takashi Kurahashi, et al. (2026). An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report.. Cureus, 18(4), e106460. https://doi.org/10.7759/cureus.106460
MLA
Terumi Shirane, et al.. "An In-Field Recurrent Cervical Cancer Case After Chemoradiotherapy With a Marked Response to Pembrolizumab Combined With TC (Paclitaxel-Carboplatin) Therapy: A Case Report.." Cureus, vol. 18, no. 4, 2026, pp. e106460.
PMID
41943793 ↗
Abstract 한글 요약
Recurrent cervical cancer after definitive concurrent chemoradiotherapy (CCRT), particularly in-field recurrence, is associated with poor prognosis and limited curative options. The efficacy of immune checkpoint inhibitor therapy combined with chemotherapy in this setting remains unclear. We report the case of a 32-year-old woman with in-field recurrent cervical squamous cell carcinoma (SCC) following definitive CCRT. The recurrent tumor was PD-L1 positive (combined positive score (CPS) ≥1). She received combination therapy with paclitaxel, carboplatin, and pembrolizumab. Marked tumor regression was observed, and the triplet regimen was continued for 16 cycles due to ongoing clinical benefit, followed by pembrolizumab monotherapy for a total of 35 cycles. The patient maintained good performance status, without severe adverse events, and remains recurrence-free 10 months after treatment completion. Pembrolizumab combined with TC (paclitaxel-carboplatin) therapy may be an effective treatment option for selected patients with unresectable in-field recurrent cervical cancer. Further evidence is required to clarify the optimal duration of combination therapy and the timing of transition to immune checkpoint inhibitor maintenance.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- [Update on the regression grading of non-small cell lung cancer].
- Comparison of different mRNA testing technologies with HPV DNA testing for predicting ASCUS triage and post-cone excision outcomes: a systematic review and meta-analysis.
- A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review.
- The role of ovarian transposition prior to pelvic radiation: A review.
- Subsequent primary cancer incidence in cervical cancer survivors: insights from a comprehensive cohort study utilizing combined Japanese population-based cancer registries.
- Inulin-Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy.